Close Menu

MIT researcher Mark Bear says that biotechs hold the key to treating autism and some forms of mental retardation, with the drugs that are already on their lab shelves, says the Forbes Treatments blog's Robert Langreth. Bear's "radical" new theory suggest that a specific class of drug already developed by drug companies may help patients with an inherited disease, fragile X syndrome, which is thought to be a cause of autism.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.